Spinal muscular atrophy: Gene therapy approved by NHS

Spinal muscular atrophy: Gene therapy approved by NHS A life-changing drug has been approved by the NHS to treat babies with a rare fatal genetic disorder.

The gene therapy Zolgensma offers hope to infants with a type of severe spinal muscular atrophy (SMA).

With a list price of £1.79m it could become the most expensive drug ever approved by the National Institute for Health and Care Excellence. BBC News